Merck & Company Inc (MRK)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Merck & Company Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 130.20 $ — 97% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 3.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 26
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.76 | 2.55 – 3.19 | 66,887 | -69.3% | 21 |
| 12/31/2027 | 9.68 | 8.90 – 10.34 | 70,170 | 251.0% | 20 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.26 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.47 | – | 15,624 | 6.80 | 24.00 | 3,450 | 2,513 |
| 2025: Q1 | 2.01 | 6.70 | 15,619 | -1.00 | 32.50 | 2,500 | 1,172 |
| 2025: Q2 | 1.76 | -17.80 | 15,800 | -1.90 | 28.00 | 3,293 | 2,529 |
| 2025: Q3 | 2.32 | 86.40 | 17,183 | 3.20 | 33.70 | 7,822 | 6,835 |
| 2025: Q4 | 1.19 | -19.20 | 16,324 | 4.50 | 18.20 | 2,857 | 1,824 |
| 2026: Q1 | -1.72 | -185.50 | 16,286 | 4.30 | -26.00 | 3,918 | 2,927 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 39,807 | 5,499 | 3,920 | 1.41 | 10,376 | 40,088 | 95,377 |
| 2017 | 40,122 | 6,797 | 2,394 | 0.87 | 6,447 | 34,336 | 87,872 |
| 2018 | 42,294 | 8,931 | 6,220 | 2.32 | 10,922 | 26,701 | 82,637 |
| 2019 | 39,121 | 7,926 | 9,843 | 3.82 | 13,440 | 25,907 | 84,397 |
| 2020 | 41,518 | 5,548 | 7,067 | 2.78 | 10,253 | 25,317 | 91,588 |
| 2021 | 48,704 | 13,199 | 13,049 | 5.14 | 14,109 | 38,184 | 105,694 |
| 2022 | 59,283 | 18,282 | 14,519 | 5.71 | 19,095 | 45,991 | 109,160 |
| 2023 | 60,115 | 2,954 | 365 | 0.14 | 13,006 | 37,581 | 106,675 |
| 2024 | 64,168 | 20,221 | 17,117 | 6.74 | 21,468 | 46,313 | 117,106 |
| 2025 | 64,926 | 23,486 | 18,254 | 7.28 | 16,472 | 52,606 | 136,866 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Merck & Co., Inc.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 73,000 |
| Headquarters | Rahway, NJ |
| Address | 126 East Lincoln Avenue, 07065 Rahway, United States |
| Phone | 908 740 4000 |
| Website | merck.com |
| IPO Date | 13. Jan 1978 |
| ISIN | US58933Y1055 |
| Stock Split | 1048:1000 on 06/03/2021 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert M. Davis J.D. | Chairman, President & CEO | 1967 |
| Caroline A. Litchfield | Executive VP & CFO | 1969 |
| Jennifer L. Zachary J.D. | Executive VP & General Counsel | 1978 |
| Dean Y. Li M.D., Ph.D. | Executive VP & President of Merck Research Laboratories | 1963 |
| Dalton E. Smart III | Senior VP of Finance, Principal Accounting Officer & Global Controller | 1967 |
| David Michael Williams | Executive VP and Chief Information & Digital Officer | 1969 |
| Peter Dannenbaum | Vice President of Investor Relations | – |
| Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications | 1966 |
| Betty D. Larson | Executive VP & Chief Human Resources Officer | 1976 |
| Richard R. DeLuca Jr. | Executive VP & President of Merck Animal Health | 1963 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.